With rich business and medical expertise, the Asarina Pharma team is united by its vision of bringing the world’s first targeted therapy for PMDD, the severest form of PMS, to a market with next to no alternative treatments. With approx. 4 million potential sufferers in the US and 6 million in Europe, it’s time for a treatment, for PMDD.
Asarina Pharma is a lean and efficient organization with a seasoned management team with extensive pre-clinical, clinical development, project management and market experience. The management team is supervised by a board comprising experienced individuals from the pharmaceutical industry and venture capital field.
Chief Executive Officer
MD, with 20 years of experience from pharmaceutical companies Novo Nordisk and Ferring Pharmaceuticals. Recent 10 years in biotechnology as CEO of Nasdaq listed Egalet and as serial Danish biotech entrepreneur. Founder or cofounder of ARTS Biologics in fertility treatment in 2011; Adenium Biotech in antimicrobial peptides and multi resistant bacteria in 2011 and finally Defensin Therapeutics in microbiota modulating defensins. Board member of Danish Biotech Association.
SHAREHOLDING: 330,124 shares, held privately and through related parties.. 6,152,674 warrants which give the right to subscribe to 246,106 new shares.
Chief Science Officer
MD, PhD, co-founder and CEO of Umecrine AB, is professor at the Department of Clinical Science, Obstetrics and Gynecology, Umeå University. He is also head of the Umeå Neurosteroid Research Center. Professor Bäckström’s main focus of research since 1972 is the effect of sex and stress hormones on the brain and conditions induced by these hormones, he has more than 400 scientific publications within this area.
SHAREHOLDING: 315,338 shares, held privately and through related parties. 1,025,445 warrants which give the right to subscribe to 41,017,9 new shares.
Chief Operating Officer
PhD, has previous experience from clinical and pre-clinical project management within biotech companies active in the areas of diabetes and cognitive impairment. Moreover, she has some 20 years of experience in human experimental and clinical scientific work at the Karolinska Institute and she has more than 70 scientific publications, mainly within the area of physiology, endocrinology and metabolism.
SHAREHOLDING: 5,000 shares, held privately and through related parties. 2,050,891 warrants which give the right to subscribe to 82,035 new shares.
With a Ph.D. in Polymer Chemistry and Polymer Technology, Sven Göthe has more than 30 years’ experience of product development, project management, manufacturing and commercialization of development projects. For 19 years he has run his own commercialization consultancy, acting as senior expert of upscaling production for many innovative pharma and life science companies. He has held different positions at Pharmacia & Upjohn and Fresenius Kabi AB.
SHAREHOLDING: 10,000 shares, held privately and through related parties.
Jakob Dynnes Hansen
Chief Financial Officer
MSc, MBA, has more than 25 years of combined experience from biotech and financing. Prior to joining Asarina, he was the CFO for more than 9 years at Evolva, a Swiss public biotech company. At Evolva, he played a key role in the company’s listing in 2009 and several subsequent financings. Previously, he was CFO at two Danish biotech companies, Nuevolution and Zealand Pharma. Before moving into biotech, Mr Hansen was a senior member of the Corporate Finance Team at Unibank (now Nordea) and he has been Head of Market Research at Novo Nordisk Jakob has an MSc in Economics from University of Copenhagen and an MBA from INSEAD.
SHAREHOLDING: No shares, 1,538,168 warrants which give the right to subscribe to 61,526 new shares.
Chief Medical Officer
Märta Segerdahl has over 25 years’ clinical and strategic experience in anaesthesiology and pain medicine, including menstrual migraine. She gained her Medical License and Doctorate from Karolinska Institutet, and was a senior consultant at pain clinics in Karolinska and Huddinge Hospitals in Stockholm, heading the latter. She is currently an Associate Professor at Karolinska Institutet, Stockholm, and Chief Medical Specialist for Clinical Development Neurology for Danish pharma company Lundbeck.
SHAREHOLDING: 10,000 shares, held privately and through related parties. 1,538,168 warrants which give the right to subscribe to 61,526 new shares.
Chief Business Officer
MSc in Chemistry, has 20 years of broad-based pharmaceutical and med tech. industry experience, including product development, business development and project management gained through management positions at Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn.
SHAREHOLDING: 25,000 shares held privately and through another company. 1,538,168 warrants which give the right to subscribe to 61,526 new shares.